This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision | ||
projects:workgroups:transfusion [2019/12/13 02:38] cgreich |
projects:workgroups:transfusion [2019/12/13 04:05] (current) cgreich |
||
---|---|---|---|
Line 1: | Line 1: | ||
==== OHDSI Transfusion Working Group ==== | ==== OHDSI Transfusion Working Group ==== | ||
+ | |||
+ | <WRAP box justify round> | ||
=== MISSION === | === MISSION === | ||
Line 7: | Line 9: | ||
Transfusions are special treatments which are currently in active research by the FDA BEST and the [[https://www.nhlbi.nih.gov/science/recipient-epidemiology-and-donor-evaluation-study-reds-program|REDS-IV]] program. The current OMOP CDM allows only partial capture of relevant transfusion information to support the various research use cases (see below). This Working Group intends to close that gap. | Transfusions are special treatments which are currently in active research by the FDA BEST and the [[https://www.nhlbi.nih.gov/science/recipient-epidemiology-and-donor-evaluation-study-reds-program|REDS-IV]] program. The current OMOP CDM allows only partial capture of relevant transfusion information to support the various research use cases (see below). This Working Group intends to close that gap. | ||
- | * Use Cases: | + | </WRAP> |
- | * Effect of number of units on outcomes | + | == Use Cases == |
- | * Effect of single donor vs pooled on outcomes | + | |
- | * Effect agency blood products are obtained from (such as ARC vs NYBC) on outcomes | + | |
- | * Incidence rates of severe outcomes: TRALI, TACO, Sepsis, HTRs, PTP, thrombosis and others | + | |
- | * Fatality rates of outcomes | + | |
- | * Incidence rates of outcomes by specific blood products transfused: red blood cells, plasma, platelets, full blood | + | |
- | * Incidence rates of outcomes by blood component processing: leukocyte reduction, irradiation, pathogen-reduction | + | |
- | * Incidence rates of outcomes by indication and associated procedures and other possible risk factors | + | |
- | * Incidence rates of outcomes by donor characteristics | + | |
- | * Modelling Isues: | + | * Effect of number of units on outcomes |
+ | * Effect of single donor vs pooled on outcomes | ||
+ | * Effect agency blood products are obtained from (such as ARC vs NYBC) on outcomes | ||
+ | * Incidence rates of severe outcomes: TRALI, TACO, Sepsis, HTRs, PTP, thrombosis and others | ||
+ | * Fatality rates of outcomes | ||
+ | * Incidence rates of outcomes by specific blood products transfused: red blood cells, plasma, platelets, full blood | ||
+ | * Incidence rates of outcomes by blood component processing: leukocyte reduction, irradiation, pathogen-reduction | ||
+ | * Incidence rates of outcomes by indication and associated procedures and other possible risk factors | ||
+ | * Incidence rates of outcomes by donor characteristics | ||
- | * Detailed facts about transfused units, such as | + | == Modelling Issues == |
- | * Manipulation: cultured enrichment, demineralization, genetical modification, | + | |
- | * Concentration, dosage, portioning and unit of issue, | + | |
- | * Preservation: irradiation and pathogen reduction, transport, storage, cryoprotection, | + | |
- | * monitoring: preparation, processing, mobilization, modification, quarantine, | + | |
- | * Additive, excipient and nutrient content | + | |
+ | * Detailed facts about transfused units, such as | ||
+ | * Manipulation: cultured enrichment, demineralization, genetical modification, | ||
+ | * Concentration, dosage, portioning and unit of issue, | ||
+ | * Preservation: irradiation and pathogen reduction, transport, storage, cryoprotection, | ||
+ | * monitoring: preparation, processing, mobilization, modification, quarantine, | ||
+ | * Additive, excipient and nutrient content | ||
+ | * Dose | ||
+ | * Units | ||
+ | * Route | ||
+ | * Start/End Time | ||
+ | * Multiple touch points of interest (prescribe/dispense/admin) | ||
+ | * Lab results specific to the unit for unit-specific data (product CD34+ vs patient CD34+) | ||
* [[projects:workgroups:transfusion:members|Participants]] | * [[projects:workgroups:transfusion:members|Participants]] |